	US 12,428,464 B2
	Stable fusion protein formulation
Murali Jayaraman, Kancheepuram (IN); and Lakshmi Kanakadurga M, Hyderabad (IN)
Assigned to DR. REDDY'S LABORATORIES LIMITED, Hyderabad (IN)
Appl. No. 17/058,190
Filed by DR. REDDY'S LABORATORIES LIMITED, Hyderabad (IN)
PCT Filed May 24, 2019, PCT No. PCT/IN2019/050408 § 371(c)(1), (2) Date Nov. 24, 2020, PCT Pub. No. WO2019/224842, PCT Pub. Date Nov. 28, 2019.
Claims priority of application No. 201841019605 (IN), filed on May 25, 2018.
Prior Publication US 2021/0188941 A1, Jun. 24, 2021
Int. Cl. C07K 14/705 (2006.01); C07K 1/34 (2006.01)

CPC C07K 14/70521 (2013.01) [C07K 1/34 (2013.01); C07K 2319/30 (2013.01)]

2 Claims

1. An aqueous pharmaceutical formulation of CTLA4-Ig fusion protein comprising CTLA4-Ig fusion protein, a buffer, sugar, histidine and surfactant, wherein the CTLA4-Ig fusion protein is abatacept or belatacept, and the formulation has a pH of 6.5-8.0, and wherein the weight ratio of CTLA4-Ig fusion protein to sugar is in a range of 1:0.8 to 1:0.6, and the weight ratio of the CTLA4-Ig fusion protein to histidine is in a range of 1:0.1 to 1:0.08.